Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbvie (GB:0QCV)
:0QCV
Holding GB:0QCV?
Track your performance easily
0QCV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$153.53 - $208.50
Previous CloseN/A
Volume123.97K
Average Volume (3M)4.76K
Market Cap
$315.43B
Enterprise Value$413.77B
Total Cash (Recent Filing)$6.42B
Total Debt (Recent Filing)$36.44B
Price to Earnings (P/E)62.1
Beta0.31
Next Earnings
Jan 31, 2025EPS Estimate
2.89Next Dividend Ex-Date
Jan 15, 2025Dividend Yield3.45%
Share Statistics
EPS (TTM)2.87
Shares Outstanding1,767,140,400
10 Day Avg. Volume211
30 Day Avg. Volume4,761
Standard Deviation0.10
R-Squared0.00552
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.71
Price to Cash Flow (P/CF)14.60
P/FCF Ratio13.80
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue7.45
Enterprise Value/Gross Profit12.20
Enterprise Value/Ebitda22.73
Forecast
1Y Price Target
$203.24Price Target Upside38.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
AbbVie Inc News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbbVie's core growth drivers remain intact, with a strong performance in the core portfolio and potential for additional business development.
Market PositionAbbVie is considered one of the best-positioned names in large-cap coverage, with a core business trending ahead of expectations and attractive valuation.
Product InnovationAbbVie's newer agents, Skyrizi and Rinvoq, are offsetting the volume declines of Humira and are gaining prescriber preference over biosimilars.
Bears Say
Acquisition ChallengesThe update represents negative optics after the company's $9bn acquisition of Cerevel, for which it now has limited value to show.
Drug DevelopmentAbbVie announced that emraclidine’s pivotal Phase 2 trials did not meet their primary endpoints.
Financial GuidanceManagement lowered 2024 aesthetics guidance to $5.3bn from $5.5bn, with a notable reduction in Juvederm sales expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
21.89% Mutual Funds
0.06% Other Institutional Investors
56.53% Public Companies and Individual Investors
0QCV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest share price was $153.53 and its highest was $208.50 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $315.43B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jan 31, 2025 which is in 22 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Oct 30, 2024. The company reported $3 earnings per share for the quarter, beating the consensus estimate of $2.92 by $0.08.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $6.196 which represents an annual dividend yield of 3.45%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 2.89.
How many shares outstanding does Abbvie have?
Abbvie has 1,767,140,400 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $3 in its last earnings report, beating expectations of $2.92. Following the earnings report the stock price went up 5.907%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in GB:0QCV
---
AbbVie Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$203.24 (38.31% Upside)
$203.24 (38.31% Upside)
Blogger Sentiment
Bullish
GB:0QCV Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.61%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
0QCV Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong commercial, operational, and R&D execution with significant growth from its ex-HUMIRA platform, increased revenue and EPS guidance, and successful acquisition and integration of Cerevel Therapeutics. However, challenges remain with declining HUMIRA sales, aesthetic market headwinds, and competitive pressures on IMBRUVICA.Read More>---
0QCV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
0QCV Stock 12 Month Forecast
Average Price Target
$203.24
▲(38.31% Upside)
Technical Analysis
Best Analysts Covering 0QCV
1 Year
1 Year Success Rate
35/40 ratings generated profit
1 Year Average Return
+21.38%
reiterated a buy rating 24 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.38% per trade.
---